SIT Sordina and the EIC Accelerator: FLASH Radiotherapy Waits

S.I.T. - Sordina IORT Technologies, registered in Rome with a factory in Aprilia, makes small mobile electron accelerators that deliver radiotherapy inside the operating room while a tumour bed is exposed. Its EIC project, LIACFLASH, added the ability to deliver FLASH radiotherapy, an ultra-high dose rate that in research "enables delivery of high radiation dose with significantly reduced associated radiocytotoxicity" to healthy tissue, according to CORDIS.

The European Innovation Council granted €2,499,963 towards a €3.57 million project from December 2022 to May 2025. The final report says SIT designed and validated "the first medical linear accelerator (LINAC) capable of delivering both conventional and FLASH dose-rate electron radiotherapy" for surgery, reached TRL 8, built an AI-assisted planning unit and did pre-compliance testing against safety standards. It launched a contest to lend a system to a European clinic and said talks with strategic partners had begun "although formal agreements are still under evaluation". At ESTRO 2026 SIT described FLASH as "ongoing" development alongside its conventional LIAC HWL machine, according to its announcement.

Where SIT Stands Now

SIT's recent news concerns its established machines and research platforms: a first intraoperative procedure with LIAC HWL at a hospital in Elche, Spain, in March 2026, an ElectronFlash system chosen by the University of Catania for glioblastoma research, and a research agreement with AtOMKI. In March 2026 its LIAC FLASH GT project was admitted for funding by the Italian business ministry's Sustainable Growth Fund, according to the company. SIT's ESTRO 2026 materials name a "CHC FlashPrime" platform for ultra-high dose rates as the next step towards clinical FLASH.

The Technology: Radiation in a Flash

FLASH radiotherapy delivers a dose at rates far above conventional treatment; the project says this widens the therapeutic window by harming healthy tissue less while still killing tumour cells. SIT has worked with Institut Curie since 2019, building the ElectronFlash research platform at Curie's Orsay site for in vitro and preclinical studies. LIACFLASH is meant to bring this into the operating room, and also to treat superficial tumours through the skin, without shielding the room.

What the EIC Project Promised, and What CORDIS Shows

The project promised a LIACFLASH system for cancer treatment, and the report documents a validated TRL 8 machine with planning software and three new patent applications. Moving it to patients requires certification and clinical trials, neither of which is reported as done. CORDIS still lists the project as signed.

1. FLASH-capable IOeRT linacDeliveredTRL 8.
2. AI planning unitDeliveredPer final report.
3. Regulatory compliancePre-complianceNo certification reported.
4. Clinical useNot yetNo FLASH patients.

The Money

SIT has not published revenue figures, and its Italian filings are not freely available online. The report says co-investment interest was registered but no agreement was reached by the end of the project. No EIC Fund investment has been announced; the award was grant first.

What Cannot Be Checked

Why Europe Should Care

The report says about two in three cancer patients receive radiotherapy. SIT is a European manufacturer of the accelerators that could deliver it. The EIC paid for the machine; the clinical proof is still ahead.

The Verdict

SIT and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.